Diagnosis of *Streptococcus pneumoniae* infection using circulating antibody secreting cells

Shuya Kyu1*, Richard P. Ramonell1*, Merin Kuruvilla1, Colleen S. Kraft2,3, Yun F. Wang3, Ann R. Falsey4,5, Edward E. Walsh4,5, John L. Daiss6,7, Simon Paulos8, Gowrisankar Rajam8, Hao Wu9, Srinivasan Velusamy10, F. Eun-Hyung Lee1*

1 Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America, 2 Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, United States of America, 3 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America, 4 Division of Infectious Diseases, Department of Medicine, University of Rochester Medical Center, Rochester, New York, United States of America, 5 Rochester General Hospital, Rochester, New York, United States of America, 6 Center for Musculoskeletal Research and Department of Orthopaedics, University of Rochester Medical Center, Rochester, New York, United States of America, 7 MicroB-plex, Inc., Atlanta, Georgia, United States of America, 8 Merck & Co., Inc., Kenilworth, New Jersey, United States of America, 9 Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, United States of America, 10 Division of Bacterial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

* These authors contributed equally to this work.

**Abstract**

**Background**

*Streptococcus pneumoniae* infections cause morbidity and mortality worldwide. A rapid, simple diagnostic method could reduce the time needed to introduce definitive therapy potentially improving patient outcomes.

**Methods**

We introduce two new methods for diagnosing *S. pneumoniae* infections by measuring the presence of newly activated, pathogen-specific, circulating Antibody Secreting Cells (ASC). First, ASC were detected by ELISpot assays that measure cells secreting antibodies specific for signature antigens. Second, the antibodies secreted by isolated ASC were collected in vitro in a novel matrix, MENSA (media enriched with newly synthesized antibodies) and antibodies against *S. pneumoniae* antigens were measured using Luminex immunoassays. Each assay was evaluated using blood from *S. pneumoniae* and non-*S. pneumoniae*-infected adult patients.

**Results**

We enrolled 23 patients with culture-confirmed *S. pneumoniae* infections and 24 controls consisting of 12 non-*S. pneumoniae* infections, 10 healthy donors and two colonized with *S. pneumoniae*. By ELISpot assays, twenty-one of 23 infected patients were positive, and all...
Introduction

Streptococcus pneumoniae (S. pneumoniae) is the most frequent cause of community-acquired pneumonia (CAP) [1], and associated with bacteremia in 25% of cases [2]. Globally, infection with S. pneumoniae is responsible for 1.6 million deaths annually [3], and is a major cause of vaccine-preventable deaths among children [4]. Furthermore, S. pneumoniae is also a leading cause of morbidity and mortality among the elderly [5].

The early identification of S. pneumoniae infections can affect outcomes for individual patients and the population at large. Diagnosis is essential for antibiotic de-escalation in infected patients since overuse of broad-spectrum antibiotics contributes to antimicrobial resistance [6]. However, conventional culture-based identification and molecular assays have recognized limitations. The current gold standard for diagnosing S. pneumoniae in CAP infections consists of positive sputum cultures, blood cultures, or urinary antigen tests in adults with pneumonia [7]. Culture-based diagnosis requires bile solubility and optochin susceptibility testing, but the reliability can on rare occasions be compromised by bile-insoluble [8, 9] and optochin-resistant strains. In addition, prior antimicrobial treatment may result in false negative diagnoses [4]. Since S. pneumoniae is a known colonizer of the respiratory tract, direct pathogen detection in sputum alone does not define it as the causative pathogen [10]. Initially, urinary antigen testing were thought to have high sensitivity and specificity; however, multiple later studies showed sensitivity of 60-65% and much lower after the introduction of the 13-valent polysaccharide vaccine (PCV13) [11]. Additionally, serological assays for S. pneumoniae have been problematic since they rely on both acute and convalescent titers of antibody responses against capsular polysaccharides. Moreover, exposure to S. pneumoniae early in life induces seroconversion against homologous capsular polysaccharides thereby limiting the diagnostic utility of serum-borne antibodies [12]. Due to the lack of sensitive and specific diagnostic assays, guidelines for CAP have discouraged use of serological diagnosis in non-hospitalized patients [13].

An alternative approach is to capture antibodies secreted by newly activated antibody secreting cells (ASC) that emerge into the blood during the acute infection. These circulating ASC ultimately migrate to the bone marrow, spleen, or lung to clear the infection and provide long-term protective antibodies [14]. Interestingly, only during active infection do the ASC circulate in the blood. Thus, measuring antibodies from circulating ASC is an underappreciated approach for microbiologic diagnosis [15–17]. The transient appearance of the ASC in blood occurs in both bacterial and viral infections [16–18]. ASC appear as early as two days post-symptom onset (DPSO) and disappear when the infection has resolved [17]. These attributes have sparked interest in the development of assays using pathogen-specific ASC for diagnosis of active infections [18–20]. Direct enumeration of ASC by ELISPOT assays or
measurement of antibodies from circulating ASC collected in vitro in a novel matrix, MENSA (media enriched with newly synthesized antibodies), have been shown to be effective diagnostics [16–20].

In this paper, we evaluated the circulating ASC response to four signature antigens in adult patients with *S. pneumoniae* infection by both ELISpot and MENSA assays. We show that ASC circulating during the acute infection secrete anti-pneumococcal antibodies, and that this approach could be potentially utilized to identify the often difficult to diagnose *S. pneumoniae* infections.

**Methods**

**Institutional approval**

All research was approved by the Emory Institutional Review Board. Informed consent was obtained from all participants.

**Human subjects**

Patients were enrolled from Emory University Hospital, Emory University Hospital Midtown, Emory Saint Joseph’s Hospital, and Grady Memorial Hospital in Atlanta, Georgia. We enrolled patients 21-85 years old who had cultures positive for *S. pneumoniae* (n = 23) or other pathogens (n = 12). Patients on immunosuppressive medications were excluded; however, HIV patients on chronic anti-retroviral therapy were included. Ninety-one healthy adults were enrolled as controls and evaluated for colonization. All protocols were approved by the Emory institutional review board. Written consent was obtained from each patient or a legally authorized representative (LAR), oftentimes a family member, if the patient was not able to consent.

**Blood culture diagnosis and patient recruitment**

Blood was collected from patients with positive cultures for *S. pneumoniae* and non-*S. pneumoniae* pathogens. Bacterial cultures were performed by the Emory University Hospital microbiology laboratory. Species were identified using standard biochemical and molecular methods described previously [21]. Briefly, peripheral blood samples were collected in bottles containing culture medium and were continuously monitored during incubation at 37˚C for five days. For respiratory cultures and wounds, samples were plated upon receipt and grown in CO\textsubscript{2} incubators. Once growth of bacterial colonies was detected, Gram-staining and subcultures were performed to enable genus and species identification. Patients with positive cultures were enrolled between 1-17 days after confirmation. Six patients who only produced samples after 4 days post-confirmation were used to determine the window of collection in Fig 3. Patient information for those with *S. pneumoniae* and non-*S. pneumoniae* infections is presented in Table 1.

**Nasopharyngeal swabs and lytA PCR**

Nasopharyngeal swab samples were obtained from 91 healthy adults and PCR targeting the major autolysin gene, lytA, was performed as described previously [22].

**Peripheral Blood Mononuclear Cell (PBMC) isolation**

Peripheral blood (20 mL) was collected in sodium heparin tubes and processed within 8 hours. PBMC were isolated by density gradient centrifugation at 800×g for 20 minutes. The PBMC were washed 5 times with RPMI at 500×g for five minutes. Viability was assessed by trypan blue exclusion; live cells were counted using a Bio-Rad TC20\textsuperscript{TM} automated cell counter. Cells
were incubated in RPMI with 10% fetal bovine serum (R10) at 37˚C with 5% CO₂ until use in the ELISpot assay.

**MENSA generation**

PBMC were resuspended in R10 at 2.5×10⁶ cells/mL; 5×10⁵ PBMC (200 μL) were added to culture wells coated with bovine serum albumin (BSA) and incubated for 16-24 hours, 37˚C, 5% CO₂. MENSA supernatant (150 μL) was collected from each well and stored frozen at -80˚C until use.

**Antigens**

PsaA (Serotype 6B) was generously provided by Edwin Ades (Sanofi-Pasteur, Toronto, Ontario, Canada [23]). PspA (clades 2 (Rx1), 3 and 4 (JCP#56)) were obtained from BEI Resources (NR-33178, NR-33179, and NR-33180) and CWPS was purchased from Statens Serum Institut (1:1 mixture of a noncapsulated former serotype 2 strain and 22F-R-LSA/ICS) (Cat. #68866). Recombinant PcsB (serotype 4, TIGR4) was synthesized and purified by GenScript as described previously [24, 25].

**Enzyme-Linked Immunospot (ELISpot) assay**

ELISpot plates (Millipore) were coated with antigens diluted in phosphate-buffered saline (PBS): PcsB (50 μg/mL), PsaA (50 μg/mL), CWPS (50 μg/mL), and control wells with 2% BSA and performed similarly as previously described [26]. For PspA, equal amounts of clade 2, 3, and 4 proteins were combined in a single well (final concentration 50 μg/mL). Total immunoglobulin wells were coated with polyclonal anti-human IgM, IgG, or IgA, each at 10 μg/mL, in separate wells (Life Technologies). The plates were incubated 2 hours at 37˚C, or overnight at 4˚C in a humidified chamber. Coated plates were washed 3 times with 200 μL R10, and

---

**Table 1. Demographic and clinical information for infected patients.**

| Characteristic | S. pneumoniae Positive (n = 23) | S. pneumoniae Negative (n = 12) |
|---------------|-------------------------------|-------------------------------|
| Age: years (range) | 53±17 (27-83) | 48±13 (24-70) |
| Gender: number (%) | | |
| Male | 15 (68%) | 5 (41%) |
| Symptoms – no. (%) | | |
| Fever | 14 (65%) | 7 (58%) |
| Cough | 14 (64%) | 6 (50%) |
| Sputum | 13 (59%) | 4 (33%) |
| Fatigue | 15 (70%) | 7 (58%) |
| Malaise | 19 (90%) | 10 (91%) |
| ICU | 7 (35%) | 6 (50%) |
| Ventilator | 2 (10%) | 1 (8%) |
| Sepsis | 4 (25%) | 5 (42%) |
| Comorbidities – no. (%) | | |
| Transplant | 1 (5%) | 3 (27%) |
| Cancer | 6 (30%) | 2 (18%) |
| HIV | 4 (24%) | 2 (18%) |
| HBV | 0 (0%) | 0 (0%) |
| Splenectomy | 1 (5%) | 0 (0%) |
| B cell biologics | 0 (0%) | 0 (0%) |

https://doi.org/10.1371/journal.pone.0259644.t001
blocked with R10, 2 hours, 37˚C. PBMC (250,000-500,000) were incubated on the plates for 16-24 hours. For detection, the plates were washed with PBS-0.1% Tween (PBS-T) 6 times and incubated with alkaline phosphatase-conjugated anti-IgM, anti-IgA, or anti-IgG antibody (1 μg/mL; Jackson Immunoresearch) for 2 hours, RT. The plates were washed 3 times with PBS-T and soaked in PBS-T for 1 hour and then developed using the Vector Blue Alkaline Phosphatase Substrate kit (SK-5300). Spots were visualized and enumerated using a CTL Immunospot reader.

**Exclusion of indeterminate assays**

Assays with ≥4 positive spots in the negative control wells were indicative of non-specific antibody binding. Assays with <100 spots per 500,000 PBMC in the total IgG well were considered indeterminate and excluded from the final analysis.

**Luminex immunoassay antigen-bead conjugation**

Pneumococcal protein antigens PcsB, PsaA, and PspA were covalently conjugated to carboxylate-modified, spectrally-distinct Luminex microspheres (beads) using the carbodiimide reaction [27]. Beads (12.5×10^6 beads/mL) were activated in 10 μL/mL of sodium phosphate buffer (pH6.2) (Cat#S0741, Sigma-Aldrich, St. Louis, MO) containing 2.5 mg of N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide (EDC, Cat#E7750, Sigma-Aldrich) and 2.5 mg of N-Hydroxysuccinimide (NHS, Cat#130672, Sigma-Aldrich). After 20 min incubation, RT, with inversion and rotation, beads were harvested by centrifugation at 12,000×g for 5 min and resuspended in 500 μL 2-(N-Morpholino) ethanesulfonic acid hydrate (MES, Cat#M8250, Sigma-Aldrich) containing the protein antigen. After 2h incubation, RT, the beads were washed once with blocking buffer (PBS-1% BSA; Cat#05470, Sigma-Aldrich), resuspended in 500 μL blocking buffer, and incubated for 30 min, RT, with inversion and rotation. Beads were washed twice with blocking buffer and refrigerated in 1 mL storage buffer (PBS-0.5% BSA).

**S. pneumoniae multi-antigen luminex immunoassay**

Each assay plate included a standard reference serum (CDC 887, In-house human polyclonal serum), diluted 4-fold for 8 dilutions starting at 1/20, and an internal quality control (QC) serum. Test serum samples were diluted 2-fold for 7 dilutions starting at 1/100. IgG-free human serum (Sigma-Aldrich), and assay buffer blanks were used as controls. All dilutions of QC samples, reference standards, and samples were carried out in 96-well round bottom titer plates (Dilution plate, Cat#CLS3799, Sigma-Aldrich). 96-well multiscreen HTS filter plates (MABVN1250, Millipore Corp, Billerica, MA), pre-wet with 100 μL/well assay buffer (PBS-0.1% BSA) were aspirated and antigen-conjugated beads (2500 beads/region/well; 25 μL/well) were added. From the dilution plate, 25 μL reference standards, QC samples and serum samples were transferred to the filter plate with beads and incubated in the dark for 30-50 min, RT, with agitation. The plate was aspirated and washed three times with 100 μL assay buffer. To each well, 50 μL of a 1/200 dilution of R-phycoerythrin-conjugated Goat anti-human Fcγ specific IgG (GTIGF-001, Moss Inc., Pasadena, MD) in PBS was added and incubated for 10-30 min, RT, with agitation. After 3 washes, the beads were resuspended in 130 μL assay buffer. The plate was read in a Luminex 200 reader (Luminex Corp., Houston, TX). The reporter signal value was expressed as the median fluorescent intensity (MFI) and increased monotonically with bead-bound antibody density.
Data analysis
Masterplex CT/QT data-analysis software (MiraiBio) was used for data reduction and analysis. The program utilizes a four-parameter, logistic-log (4-PL), robustly weighted function to model the test curves from the MFI of dilution points of the reference standard. Sample concentrations were calculated by interpolating the MFI to the reference standard curve. Standard curve fitting, sample concentrations and QC criteria were calculated independently for each antigen.

Results
Study subjects
Twenty-three patients with *S. pneumoniae*-positive infections and twelve subjects with infections caused by other organisms (*S. pneumoniae*-negative) were enrolled, along with 91 healthy controls. Of those with *S. pneumoniae* infections, sixteen were bacteremic, five were positive by sputum culture only, and two had positive wound cultures. The primary source of *S. pneumoniae* infection was pneumonia in nineteen patients, bronchitis in one, sinusitis in one, paraspinal abscess in one, and skin and soft tissue infection in one. Eighteen patients had lobar pneumonia while one had pneumonia with empyema. Most patients initiated antimicrobial therapy at the time of admission. All non-pneumococcal infections were bacteremic, and included five with *Staphylococcus aureus*, one each with *Klebsiella pneumoniae*, *Enterococcus faecium*, *Escherichia coli*, yeast, and three unidentified bacteremias (Gram-variable rods, *Staphylococcus* species, alphahemolytic *Streptococcus* species). Among the healthy subjects, two tested positive for *S. pneumoniae* nasopharyngeal colonization by lytA qPCR; Ct values were 24.55 and 35.14 for COL1 and COL2, respectively. Peripheral blood was collected from all *S. pneumoniae*-infected subjects (n = 23), all non-*S. pneumoniae*-infected patients (n = 12), colonized control subjects (n = 2) and randomly selected healthy controls negative for *S. pneumoniae* colonization (n = 10). Patient demographic information and symptoms of infected subjects are presented in Table 1.

ELISpot assays detect host anti-*S. pneumoniae* responses
Representative ELISpot images from each of these 4 subject groups demonstrate evidence of IgG ASC in all groups and illustrate antigen-specific responses from circulating ASC only in the *S. pneumoniae*-infected patients (Fig 1).

*S. pneumoniae*-specific ELISpot assays in *S. pneumoniae* infections and non-*S. pneumoniae* infection controls
IgG ELISpot assays were used to compare the detection of ASC specific for *S. pneumoniae* antigens in all four groups (Fig 2A). Among patients with *S. pneumoniae* infections, mean spot totals for each antigen were highest for PcsB (12.9 spots/well, 95% CI 5.5 to 20.4) followed by PspA (5.8 spots/well, 95% CI 2.4 to 9.1), CWPS (4.3 spots/well, 95% CI 1.7 to 6.8), and PsaA (4.0 spots/well, 95% CI 1.0 to 7.1) (Fig 2B). Among patients in the non-*S. pneumoniae*-infected population, none of the patients had more than four spots/well in the four *S. pneumoniae* antigens tested (Fig 2C). We used the Poisson distribution to model the counts from the non-*S. pneumoniae* group and calculated the C₀ value so that the Poisson test p-value is less than 0.01. For IgG, the C₀ for antigens PcsB, PsaA, PspA, CWPS were 2, 3, 2, 3, respectively. The C₀ distinguished subjects with documented *S. pneumoniae* infections from healthy controls, colonized subjects and those infected with other pathogens.

Overall, 91% (21/23) of patients with *S. pneumoniae* infections tested positive for at least one of the four antigens tested (Table 2). PcsB had the highest rate of detection (61%, 14/23)
followed by PspA (57%, 13/23), CWPS (39%, 9/23), and PsaA (35%, 8/23). Among patients with non-\textit{S. pneumoniae} infections, none (0/12) were positive for any of the antigens tested.

\textit{S. pneumoniae-specific IgG ELISpot assays in healthy controls and colonized subjects}

To determine the background response in healthy individuals, we tested ASC from 10 healthy, non-colonized subjects and the two colonized subjects. For both healthy subject groups, no more than 1 spot/well was detected for any of the antigens tested (Fig 2D). All healthy controls and colonized subjects were negative.

\textbf{IgG ELISpot assays are more sensitive and specific than those for IgM or IgA}

All PBMC specimens from patients with bacteremia were screened for IgM, IgG, and IgA antibody responses specific for the four \textit{S. pneumoniae} cell wall antigens. Among the antibody isotypes, the sensitivity of the IgG assay was greater (91%, 21/23) than either IgA (75%, 15/20) or IgM (23%, 5/22) in detecting \textit{S. pneumoniae} infections (Table 2). IgG (100%) had a superior
Antibody secreting cells produce antibodies specific for the four *S. pneumoniae* antigens in blood of patients with *S. pneumoniae* infections. Numbers of IgG-secreting cells (per 500,000 cells) specific to antigens (PcsB, PsaA, PspA, CWPS) in blood samples of patients with *S. pneumoniae-*infection (SP1-23), patients with non-*S. pneumoniae*-infection (NSP1-12), healthy controls with *lytA*-negative nasal swabs (H1-10), and *lytA*-positive nasal swabs (COL1-2) as measured by ELISpot (A). Spot numbers greater than C0 for each antigen are highlighted in gray.

Summary of the number of spots in ELISpot immunoassays positive for each of four antigens in patients with *S. pneumoniae* infection (B; n = 23), patients with non-*S. pneumoniae* infection (C; n = 12) and healthy controls (D; n = 12). Healthy controls include subjects colonized (open triangles; n = 2) and not colonized (closed circles; n = 10) as determined by *lytA* PCR. Each data point represents one patient’s response specific for the indicated antigen in the number of spots/well minus background. The dashed horizontal lines indicate the diagnostic value, C0, the cut-off.

### Table A

| SP Positive | PcsB | PsaA | PspA | CWPS | Total IgG |
|-------------|------|------|------|-------|-----------|
| SP1         | 2    | 6    | 0    | 0     | 0         |
| SP2*        | 0    | 2    | 4    | 3     | 2         |
| SP3*        | 0    | 2    | 4    | 3     | 2         |
| SP4         | 12   | 0    | 0    | 0     | 19        |
| SP5         | 10   | 0    | 2    | 26    | 32        |
| SP6         | 11   | 0    | 4    | 1     | 16        |
| SP7         | 9    | 0    | 0    | 0     | 9         |
| SP8*        | 3    | 1    | 5    | 3     | 11        |
| SP9         | 1    | 33   | 20   | 8     | 0         |
| SP10*       | 32   | 0    | 0    | 0     | 32        |
| SP11        | 1    | 0    | 0    | 4     | 5         |
| SP12*       | 4    | 0    | 0    | 0     | 4         |
| SP13*       | 4    | 0    | 0    | 0     | 4         |
| SP14        | 1    | 1    | 0    | 11    | 12        |
| SP15*       | 1    | 0    | 3    | 15    | 19        |
| SP16        | 6    | 1    | 6    | 8     | 22        |
| SP17        | 74   | 11   | 4    | 2     | 92        |
| SP18        | 41   | 6    | 6    | 5     | 59        |
| SP19        | 1    | 0    | 0    | 0     | 1         |
| SP20        | 41   | 7    | 3    | 0     | 51        |
| SP21        | 1    | 4    | 12   | 4     | 19        |
| SP22        | 8    | 12   | 0    | 2     | 22        |
| SP23        | 16   | 9    | 17   | 1     | 51        |

### Table B

| SP Negative | PcsB | PsaA | PspA | CWPS | Total IgG |
|-------------|------|------|------|-------|-----------|
| NSP1        | 0    | 0    | 0    | 0     | 0         |
| NSP2        | 0    | 1    | 2    | 2     | 5         |
| NSP3        | 1    | 0    | 0    | 0     | 1         |
| NSP4        | 0    | 0    | 0    | 0     | 0         |
| NSP5        | 0    | 0    | 0    | 0     | 0         |
| NSP6        | 0    | 0    | 1    | 0     | 1         |
| NSP7        | 0    | 1    | 0    | 0     | 1         |
| NSP8        | 0    | 0    | 0    | 0     | 0         |
| NSP9        | 1    | 1    | 0    | 3     | 5         |
| NSP10       | 1    | 0    | 3    | 0     | 4         |
| NSP11       | 0    | 1    | 0    | 0     | 1         |
| NSP12       | 0    | 0    | 0    | 0     | 0         |

### Table C

| Healthy | PcsB | PsaA | PspA | CWPS | Total IgG |
|---------|------|------|------|-------|-----------|
| H1      | 1    | 0    | 0    | 0     | 1         |
| H2      | 0    | 0    | 0    | 1     | 1         |
| H3      | 0    | 0    | 0    | 0     | 0         |
| H4      | 0    | 0    | 0    | 1     | 1         |
| H5      | 0    | 0    | 0    | 0     | 0         |
| H6      | 0    | 0    | 0    | 0     | 0         |
| H7      | 0    | 0    | 0    | 0     | 0         |
| H8      | 0    | 0    | 0    | 0     | 0         |
| H9      | 0    | 0    | 0    | 0     | 0         |
| H10     | 0    | 0    | 0    | 0     | 0         |

### Table D

| Colonized | PcsB | PsaA | PspA | CWPS | Total IgG |
|-----------|------|------|------|-------|-----------|
| COL1      | 0    | 0    | 0    | 0     | 0         |
| COL2      | 0    | 0    | 0    | 0     | 0         |

Unmarked Bacteremia
* Respiratory Culture
† Wound Culture
specificity compared to IgA (78%). In addition, all patients positive for \textit{S. pneumoniae}-specific IgA or IgM were also positive for \textit{S. pneumoniae}-specific IgG. Thus, in the following experiments, we based the diagnostic assay on the detection of antigen-specific IgG alone.

\textbf{\textit{S. pneumoniae}-specific IgG response is highest during the first four days following confirmation}

To identify the optimal time for diagnostic sample collection, blood samples were collected 1-17 days following a positive blood culture. Analysis of the time course of the pathogen-specific IgG response showed that most of the ASC response occurred during the first four days following culture confirmation and declined thereafter (Fig 3A–3D). Between 35 and 61% of patients produced ASC secreting IgG for each antigen during the first four days following confirmation; however, after day 5, the frequency of positive ASC decreased substantially (0-25%). In \textit{S. pneumoniae} infection, it is often difficult to know the timing of inoculation; however, we identified symptom onset based on the history. On average, patients presented four days after symptom onset. Blood cultures were sent at presentation and cultures were confirmed positive approximately 48 hours later. Patients were recruited within four days of confirmation, which was on average 10 days from time of symptom onset, with a range of 5-19 days.

\textbf{Using all four antigens detects more positive patients}

Receiver operating characteristic (ROC) curves for the four antigens show that PcsB had the highest area under the curve, AUC = 0.95, while PsaA had the lowest (AUC = 0.61; Fig 4A). After observing that \textit{S. pneumoniae}-infected patients presented with different patterns of antibody responses to the four antigens (Fig 2A), we hypothesized that the diagnostic test accuracy could be improved by summing the number of spots from all four antigen wells within a single sample. Conservatively, the non-zero \(y\)-intercept, which indicates the spot number with the highest sensitivity without any false positives, increased to 80% compared to 62% for PcsB alone, showing the benefit of having multiple antigens for the detection assay (Fig 4B). While anti-PcsB IgG alone was a strong predictor of \textit{S. pneumoniae} infection (14/23), the addition of the three other antigens enabled the identification of seven additional positive patients (21/23).

\textbf{IgG ELISpot data correlates with antigen-specific antibody levels in MENSA}

Finally, we evaluated a multiplex Luminex assay to detect \textit{S. pneumoniae}-specific antibodies in MENSA, a novel matrix, as an alternative to ELISpot assays. To increase the specificity of the assay, preformed antibodies present in serum were excluded by extensive washing and ASC

---

Table 2. Diagnostic performance of antibody isotypes against \textit{S. pneumoniae} cell wall antigens.

| Antibody Isotype | \textit{S. pneumoniae} infection | Non-\textit{S. pneumoniae} infection |
|------------------|---------------------------------|-----------------------------------|
|                  | Positive Test                   | Negative Test                     | Positive Test | Negative Test |
| IgG              | 21/23 (91%)                     | 2/23 (9%)                         | 0/12 (0%)    | 12/12 (100%) |
| IgA              | 15/20 (75%)                     | 5/20 (25%)                        | 2/9 (22%)    | 7/9 (78%)    |
| IgM              | 5/22 (23%)                      | 17/22 (77%)                       | 1/11 (9%)    | 10/11 (91%) |

Positive test defined as spot number greater than \(C_0\) in any single well of the four antigens tested.

https://doi.org/10.1371/journal.pone.0259644.t002
were placed in fresh media so only newly synthesized antibodies would be present. MENSA from patients with S. pneumoniae infections (n = 5) and patients with non-S. pneumoniae infections (n = 5) were tested for IgG-specific for the three antigens PcsB, PsaA, and PspA. Antigen-specific antibody levels correlated well with IgG ELISpot assays for each individual antigen with $R^2$ values of 0.92 for PspA ($p = 0.009$; Fig 5C), 0.92 for PsaA ($p = 0.089$; Fig 5B), and 0.96 for PcsB ($p = 0.003$; Fig 5A). In fact, 4 of 5 patients produced MENSA IgG antibodies reactive with one of the three antigens tested (Fig 5D) and the single patient who was not detected was positive only for the CWPS antigen that was not included in this MENSA test (Fig 2A, patient SP15). In addition, antigen-specific antibody levels were consistently negative in the MENSA collected from five patients with non-S. pneumoniae bacteremias (Fig 5D).

**Discussion**

In this proof-of-concept study, we have examined the utility of circulating ASC as biomarkers for ongoing S. pneumoniae infections in human patients. The initial objective was
identification of patients with acute infection, and as we predicted, *S. pneumoniae*-infected patients had higher frequencies of antigen-specific ASC in the blood than healthy controls, colonized subjects or patients infected with non-*S. pneumoniae* pathogens. Using the ASC response against only four antigens, we were able to distinguish *S. pneumoniae*-infected patients from healthy controls (AUC = 0.98) and from non-*S. pneumoniae*-infected patients (AUC = 0.92).

The selection of antigen targets for these immunoassays

*S. pneumoniae* has over 90 serotypes that can be distinguished by antibody responses to carbohydrate antigens [28]. However, several proteins from *S. pneumoniae* are highly conserved among the 90 serotypes [29]. We selected four candidate antigens based on demonstrated immunodominance and the ability to distinguish between infection and colonization [30].
These proteins included the pneumococcal surface adhesin A (PsaA), the protein required for cell wall separation of group B streptococci (PcsB), and pneumococcal surface protein A (PspA). PsaA is a lipoprotein that functions as a host cell adhesin [31]. PcsB is an essential hydrolase that mediates the separation of dividing cells [32]. PspA is a surface protein that inhibits complement activation thereby contributing to virulence [33]. Of these, anti-PspA and anti-PcsB are most frequently detected in serum responses [34–36]. In addition, we examined the response to the *S. pneumoniae* cell wall polysaccharide (CWPS) which is a highly conserved teichoic acid-like polysaccharide present in the cell wall and elicits a non-protective
antibody response [37]. Because it is common across multiple serotypes, it was ideal for this assay.

All four antigens had significant diagnostic utility with the highest for PcsB (AUC = 0.95) and lowest for PsaA (AUC = 0.61). The combination of all four pneumococcal antigens significantly improved the sensitivity of the assay when using a conservative C₀ value where specificity was 100%. This approach of seeking active ASCs may also differentiate the diagnosis of *S. pneumoniae* from taxonomically similar commensal species, such as *S. mitis* and *S. pseudopneumoniae* [38].

There was variability of the number of ASC for each *S. pneumoniae* antigens, highlighting the difficulty and importance of antigen selection. This could be due to differences among the patient cohort including: (1) phase of infection (during the growth phase of *S. pneumoniae*, the host may encounter increased PcsB), (2) sites of infection, and (3) variations among strains (e.g., sequence variations in target antigens and expression of alternative but functionally related proteins). There is sufficient variability among hosts and pathogens that selection of antibody response to single antigen may not always be sufficient. Thus, an ASC diagnostic assay utilizing a selection of antigens serves in a practical way to enhance analytic sensitivity. Hence the capability of detecting multiple antigens from the same ASC matrix in the MENSA platform makes it an ideal system for this diagnostic test.

**Kinetics of ASC with bacterial infection**

The levels of circulating ASC do not remain elevated indefinitely. Rather, ASC emerge into the bloodstream early in the course of the infection and decline to zero when the infection is resolved. This feature was evident in Fig 3 where ASC levels declined to background in most patients, and for most antigens, five days post-confirmation, plausibly reflecting successful antibiotic therapy initiated 4-5 days earlier. The decline in circulating ASC upon the resolution of infection further validates this approach for diagnosis of acute primary infection as well as potentially providing a biomarker of therapeutic efficacy. Since the assay is agnostic to pre-existing serum levels, it can be used for repeat infections in settings especially when serum titers are elevated [16, 20].

**Limitations and future objectives**

A limitation of the study was the modest population size with only 23 *S. pneumoniae*-positive patients and 12 *S. pneumoniae*-negative patients. Additionally, after surveying 91 subjects, we were only able to find two *S. pneumoniae*-colonized subjects. This may be in part due to the prevalence of pneumococcal vaccines contributing to a lower frequency of colonized subjects. A study in the United Kingdom found only 2.8% pneumococcal carriage in parents of young children during 2015/2016 after the introduction of PCV13 in 2010 [39]. Thus, larger study numbers will enable greater scrutiny of the specificity of each antigen as a potential diagnostic target and expanding the study to include children with invasive pneumococcal disease and children heavily colonized with *S. pneumoniae* may also be important.

**Earlier sample timing may yield improved sensitivity**

In the present study, we only analyzed samples collected 1-4 days post-confirmation or 5-9 days post-clinical presentation for most subjects. Based on the data presented in Fig 3, ASC collected after day 4 are likely to be of limited value for primary diagnosis, however, samples from earlier time points, closer to symptom onset and clinical presentation, may have higher sensitivity.
Advantages of MENSA-based assays

ELISpot or MENSA-based diagnostic methods currently take at least 24 hours; thus, improving cell preparation and dramatically reducing incubation time for ELISpot assays or antibody accumulation in MENSA are plausible improvements for making this method practical for clinical labs. Compared with the ELISpot assay, the MENSA/Luminex assay requires significantly fewer cells since the assay can detect antibodies to multiple antigens at the same time. Additionally, the MENSA assays are readily amenable for higher throughput and storage for later studies. Thus, MENSA from unidentified pneumonias can be stored and tested for emerging pathogens identified in the future.

Utilization of ASC as a diagnostic test for viral and bacterial pathogens

In this study, we show that by assessing circulating ASC, diagnosis of \textit{S. pneumoniae} bacteremic infections is possible. Similarly, circulating ASC as a diagnostic markers have been demonstrated for viral and bacterial pathogens including: Influenza virus [16, 26, 40, 41], Respiratory syncytial virus [17], \textit{Salmonella enterica} [42], \textit{Mycobacterium tuberculosis} [43–45], \textit{Staphylococcus aureus} [18, 20], and \textit{Clostridiodes difficile} [19]. Based on the other opportunities for measuring ASC in the circulation, we anticipate that other indications of \textit{S. pneumoniae} (e.g., pneumonia, meningitis) and other pathogens that cause bacteremia (e.g., \textit{Staphyloccoci}, Enterococci) will be addressable in a similar way.

Conclusion

We present a simple method for diagnosing adult patients with \textit{S. pneumoniae} infection. The method measures circulating ASC that emerge into blood early in an infection and rapidly disappear from circulation following its resolution. If proven to be more accurate and practical than routine diagnostic methods currently used, this novel immunoassay, with modest improvements, could substantially advance bacterial diagnostics.

Acknowledgments

We would like to thank Edwin Ades for his important critical reagents. We also thank Jennifer Scantlin, Sonia Ros, Claudine Nkurunziza, Julie Kozarsky, Mindy Hernandez, Saeyun Lee, John Varghese, Sang N. Le, and Martin Runnstrom for clinical chart reviews. The following reagents were obtained through BEI Resources, NIAID, NIH: \textit{Streptococcus pneumoniae} Family 1, Clade 2 Pneumococcal Surface Protein A (PspA UAB055) with C-Terminal Histidine Tag, Recombinant from \textit{Escherichia coli}, NR-33178; \textit{Streptococcus pneumoniae} Family 2, Clade 3 Pneumococcal Surface Protein A (PspA UAB099) with C-Terminal Histidine Tag, Recombinant from \textit{Escherichia coli}, NR-33179; \textit{Streptococcus pneumoniae} Family 2, Clade 4 Pneumococcal Surface Protein A (PspA UAB100) with C-Terminal Histidine Tag, Recombinant from \textit{Escherichia coli}, NR-33180. Family 1, Clade 1 Pneumococcal Surface Protein A (PspA UAB069) was generously provided by Dr. Susan Hollingshead, University of Alabama.

CDC disclaimer

The findings and conclusions detailed in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Previous presentation

Open Forum Infectious Diseases IDWeek 2016, October 2016, Atlanta GA (Poster Abstract #206).
Author Contributions

Conceptualization: Shuya Kyu, Richard P. Ramonell, Colleen S. Kraft, Gowrisankar Rajam, F. Eun-Hyung Lee.

Formal analysis: Shuya Kyu, Richard P. Ramonell, Ann R. Falsey, Edward E. Walsh, Simon Paulos, Gowrisankar Rajam, Hao Wu, Srinivasan Velusamy, F. Eun-Hyung Lee.

Funding acquisition: Gowrisankar Rajam, Srinivasan Velusamy, F. Eun-Hyung Lee.

Investigation: Shuya Kyu, Richard P. Ramonell, Merin Kuruvilla, Colleen S. Kraft, Yun F. Wang, Simon Paulos, Gowrisankar Rajam, Srinivasan Velusamy.

Methodology: Shuya Kyu, Richard P. Ramonell, Colleen S. Kraft, John L. Daiss, Simon Paulos, Srinivasan Velusamy, F. Eun-Hyung Lee.

Project administration: F. Eun-Hyung Lee.

Resources: Yun F. Wang.

Supervision: Richard P. Ramonell, F. Eun-Hyung Lee.

Validation: Shuya Kyu, Richard P. Ramonell, Yun F. Wang, F. Eun-Hyung Lee.

Visualization: Shuya Kyu, Richard P. Ramonell.

Writing – original draft: Shuya Kyu, Richard P. Ramonell, Merin Kuruvilla, F. Eun-Hyung Lee.

Writing – review & editing: Shuya Kyu, Richard P. Ramonell, Merin Kuruvilla, Colleen S. Kraft, Ann R. Falsey, Edward E. Walsh, John L. Daiss, Simon Paulos, Gowrisankar Rajam, Hao Wu, Srinivasan Velusamy, F. Eun-Hyung Lee.

References

1. Cilloniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrus A, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011; 66(4):340–6. Epub 2011/01/25. https://doi.org/10.1136/thx.2010.143982 PMID: 21257985.

2. Feldman C, Anderson R. Bacteraemic pneumococcal pneumonia: current therapeutic options. Drugs. 2011; 71(2):131–53. Epub 2011/02/01. https://doi.org/10.2165/11585310-000000000-00000 PMID: 21275443.

3. Werno AM, Murdoch DR. Medical microbiology: laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis. 2008; 46(6):926–32. Epub 2008/02/12. https://doi.org/10.1086/528798 PMID: 18260752.

4. Blaschke AJ. Interpreting assays for the detection of Streptococcus pneumoniae. Clin Infect Dis. 2011; 52 Suppl 4:S331–7. Epub 2011/04/06. https://doi.org/10.1093/cid/cir048 PMID: 21460292; PubMed Central PMCID: PMC3069982.

5. File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med. 2004; 117 Suppl 3A:39S–50S. Epub 2004/09/14. https://doi.org/10.1016/j.amjmed.2004.07.007 PMID: 15360096; PubMed Central PMCID: PMC7147208.

6. Campion M, Scully G. Antibiotic Use in the Intensive Care Unit: Optimization and De-Escalation. J Intensive Care Med. 2018; 33(12):477–55. Epub 2018/03/15. https://doi.org/10.1177/0885066618762747 PMID: 29534630.

7. Albrich WC, Madhi SA, Adrian PV, van Niekerk N, Mareletsi T, Cutland C, et al. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis. 2012; 54(5):601–9. Epub 2011/12/14. https://doi.org/10.1093/cid/cir859 PMID: 22156852; PubMed Central PMCID: PMC3275757.

8. Richter SS, Heilmann KP, Dohn CL, Riahi F, Beekmann SE, Doern GV. Accuracy of phenotypic methods for identification of Streptococcus pneumoniae isolates included in surveillance programs. J Clin Microbiol. 2008; 46(7):2184–8. Epub 2008/05/23. https://doi.org/10.1128/JCM.00461-08 PMID: 18495854; PubMed Central PMCID: PMC2446902.
9. Kellogg JA, Bankert DA, Elder CJ, Gibbs JL, Smith MC. Identification of Streptococcus pneumoniae revisited. J Clin Microbiol. 2001; 39(9):3373–5. Epub 2001/08/30. https://doi.org/10.1128/JCM.39.9.3373-3375.2001 PMID: 11526182; PubMed Central PMCID: PMC88350.

10. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4(3):144–54. Epub 2004/03/05. https://doi.org/10.1016/S1473-3099(04)00938-7 PMID: 14989500.

11. Hyams C, Williams OM, Williams P. Urinary antigen testing for pneumococcal pneumonia: is there evidence to make its use uncommon in clinical practice? ERJ Open Res. 2020; 6(1). Epub 2020/01/21. https://doi.org/10.1183/23120541.00223-2019 PMID: 31956656; PubMed Central PMCID: PMC6955439.

12. Turner P, Turner C, Green N, Ashton L, Lwe E, Jankhot A, et al. Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. Clin Microbiol Infect. 2013; 19(12):E551–6. Epub 2013/11/22. https://doi.org/10.1111/1469-0691.12266 PMID: 24255996; PubMed Central PMCID: PMC4282116.

13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27–72. Epub 2007/02/06. https://doi.org/10.1086/511159 PMID: 17279083.

14. Nguyen DC, Joyner CJ, Sanz I, Lee FE. Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells. Front Immunol. 2019; 10:2138. Epub 2019/10/02. https://doi.org/10.3389/fimmu.2019.02138 PMID: 31572364; PubMed Central PMCID: PMC6749102.

15. Carter MJ, Mitchell RM, Meyer Sauteur PM, Kelly DF, Truck J. The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications. Front Immunol. 2017; 8:630. Epub 2017/06/18. https://doi.org/10.3389/fimmu.2017.00630 PMID: 28620385; PubMed Central PMCID: PMC5451496.

16. Lee FE, Halliley JL, Walsh EE, Moscatello AP, Kmush BL, Falsey AR, et al. Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. Journal of Immunology. 2011; 186(9):5514–21. Epub 2011/03/29. https://doi.org/10.4049/jimmunol.20100292 PMID: 21441455.

17. Lee FE, Falsey AR, Halliley JL, Sanz I, Walsh EE. Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. The Journal of Infectious Diseases. 2010; 202(11):1659–66. Epub 2010/10/29. https://doi.org/10.1086/657158 PMID: 20979459; PubMed Central PMCID: PMC3107551.

18. Muthukrishnan G, Soin S, Beck CA, Grier A, Brodell JD Jr., Lee CC, et al. A Bioinformatic Approach to Utilize a Patient’s Antibody-Secreting Cells against Staphylococcus aureus to Detect Challenging Musculoskeletal Infections. Immunohorizons. 2020; 4(6):339–51. Epub 2020/06/24. https://doi.org/10.4049/immunohorizons.2000024 PMID: 32571786; PubMed Central PMCID: PMC7727182.

19. Haddad NS, Nozik S, Kim G, Ohanian S, Kraft C, Rebolledo PA, et al. Novel immunoassay for diagnosis of ongoing Clostridiodes difficile infections using serum and medium enriched for newly synthesized antibodies (MENSA). J Immunol Methods. 2020:112932. Epub 2020/11/23. https://doi.org/10.1016/j.jim.2020.112932 PMID: 33221459.

20. Oh I, Muthukrishnan G, Ninomiya MJ, Brodell JD Jr., Smith BL, Lee CC, et al. Tracking Anti-Staphylococcus aureus Antibodies Produced In Vivo and Ex Vivo during Foot Salvage Therapy for Diabetic Foot Infections Reveals Prognostic Insights and Evidence of Diversified Humoral Immunity. Infect Immun. 2018; 86(12). Epub 2018/10/03. https://doi.org/10.1128/IAI.00629-18 PMID: 30275008; PubMed Central PMCID: PMC6246899.

21. Kim J, Joo EJ, Ha YE, Park SY, Kang CI, Chung DR, et al. Impact of a computerized alert system for bacteremia notification on the appropriate antibiotic treatment of Staphylococcus aureus bloodstream infections. Eur J Clin Microbiol Infect Dis. 2013; 32(7):937–45. Epub 2013/01/31. https://doi.org/10.1007/s10096-013-1829-5 PMID: 23361401.

22. da Gloria Carvalho M, Pimenta FC, Jackson D, Roundtree A, Ahmad Y, Millar EV, et al. Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. J Clin Microbiol. 2010; 48(5):1611–8. Epub 2010/03/12. https://doi.org/10.1128/JCM.02243-09 PMID: 20220175; PubMed Central PMCID: PMC2863911.

23. De BK, Sampson JS, Ades EW, Huebner RC, Jue DL, Johnson SE, et al. Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coli. Vaccine. 2000; 18(17):1811–21. Epub 2000/03/04. https://doi.org/10.1016/s0264-410x(99)00481-8 PMID: 10699329.

24. Stamsas GA, Havarstein LS, Straume D. CHiC, a new tandem affinity tag for the protein purification toolbox. J Microbiol Methods. 2013; 92(1):59–63. Epub 2012/11/17. https://doi.org/10.1016/j.mimet.2012.11.003 PMID: 23154041.
25. Beckett D, Kovaleva E, Schatz PJ. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 1999; 8(4):921–9. Epub 1999/04/22. https://doi.org/10.1101/ps.8.4.921 PMID: 10211839; PubMed Central PMCID: PMC2144313.

26. Kyu SY, Kobie J, Yang H, Zand MS, Topham DJ, Quaataert SA, et al. Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. Journal of immunological methods. 2009; 340(1):42–7. Epub 2008/11/11. https://doi.org/10.1016/j.jim.2008.09.025 PMID: 18996127; PubMed Central PMCID: PMC4690209.

27. Staros JV, Wright RW, Swingle DM. Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem. 1986; 156(1):220–2. Epub 1986/07/01. https://doi.org/10.1016/0003-2697(86)90176-4 PMID: 3740412.

28. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015; 28(3):871–99. Epub 2015/06/19. https://doi.org/10.1128/CMR.00024-15 PMID: 2605553; PubMed Central PMCID: PMC4475641.

29. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009; 374(9700):1543–56. Epub 2009/11/03. https://doi.org/10.1016/S0140-6736(09)61114-4 PMID: 19880020.

30. Olaya-Abril A, Jimenez-Munguia I, Gomez-Gascon L, Obando I, Rodriguez-Ortega MJ. A Pneumococcal Protein Array as a Platform to Discover Serodiagnostic Antigens Against Infection. Mol Cell Proteomics. 2015; 14(10):2591–608. Epub 2015/07/15. https://doi.org/10.1074/mcp.M115.049544 PMID: 26183771; PubMed Central PMCID: PMC4597139.

31. Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesin A (PsaA): a review. Crit Rev Microbiol. 2008; 34(3-4):131–42. Epub 2008/08/30. https://doi.org/10.1080/10408410802275352 PMID: 18728990.

32. Bartual SG, Straume D, Stamsas GA, Munoz IG, Alfonso C, Martinez-Ripoll M, et al. Structural basis of PcsB-mediated cell separation in Streptococcus pneumoniae. Nat Commun. 2014; 5:3842. Epub 2014/05/09. https://doi.org/10.1038/ncomms4842 PMID: 24804636.

33. Tu AH, Fulgham RL, McCrory MA, Sztalai AJ. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun. 1999; 67(9):4720–4. Epub 1999/08/05. https://doi.org/10.1128/IAI.67.9.4720-4724.1999 PMID: 10456922; PubMed Central PMCID: PMC306800.

34. Borges IC, Andrade DC, Vilas-Boas AL, Fontoura MS, Laitinen H, Ekstrom N, et al. Detection of antibody responses against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis proteins in children with community-acquired pneumonia: effects of combining pneumococcal antigens, pre-existing antibody levels, sampling interval, age, and duration of illness. Eur J Clin Microbiol Infect Dis. 2015; 34(8):1551–7. Epub 2015/04/22. https://doi.org/10.1007/s10096-015-2385-y PMID: 25894988.

35. Posfay-Barbe KM, Galetto-Lacour A, Grillet S, Ochs MM, Brookes RH, Kraehenbuhl JD, et al. Immunity to pneumococcal surface proteins in children with community-acquired pneumonia: a distinct pattern of responses to pneumococcal choline-binding protein A. Clin Microbiol Infect. 2011; 17(8):1232–8. Epub 2011/08/24. https://doi.org/10.1111/j.1469-0691.2010.03389.x PMID: 21040158.

36. Andrade DC, Borges IC, Ivaska L, Peltova V, Meinke A, Barral A, et al. Serological diagnosis of pneumococcal infection in children with pneumonia using protein antigens: A study of cut-offs with positive and negative controls. J Immunol Methods. 2016; 433:31–7. Epub 2016/03/02. https://doi.org/10.1016/j.jim.2016.02.021 PMID: 26928648.

37. Skovsted IC, Kerr M, Sonne-Hansen J, Sauer LE, Nielsen AK, Konradsen HB, et al. Purification and structure characterization of the active component in the pneumococcal 22F polysaccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays. Vaccine. 2007; 25(35):6490–500. Epub 2007/07/28. https://doi.org/10.1016/j.vaccine.2007.06.034 PMID: 17655983.

38. Karlsson R, Gonzales-Siles L, Gomez L, Busquets A, Salva-Serra F, Jaen-Luchoro D, et al. Proteotyping bacteria: Characterization, differentiation and identification of pneumococcus and other species within the Mitis Group of the genus Streptococcus by tandem mass spectrometry proteomics. PLoS One. 2018; 13(12):e0208804. Epub 2018/12/12. https://doi.org/10.1371/journal.pone.0208804 PMID: 30532202; PubMed Central PMCID: PMC6287849; doi did not have influence on the collection, analysis, or interpretation of data, the writing of the paper, or the decision to submit for publication. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

39. Adler H, Nikolaou E, Gould K, Hinds J, Collins AM, Connor V, et al. Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010-2017. J Infect Dis. 2019; 219(12):1989–93. Epub 2019/01/29. https://doi.org/10.1093/infdis/jiz034 PMID: 30690468; PubMed Central PMCID: PMC6534187.
40. He XS, Sasaki S, Narvaez CF, Zhang C, Liu H, Woo JC, et al. Plasmablast-derived polyclonal antibody response after influenza vaccination. J Immunol Methods. 2011; 365(1-2):67–75. Epub 2010/12/25. https://doi.org/10.1016/j.jim.2010.12.008 PMID: 21182843; PubMed Central PMCID: PMC3039424.

41. Halliley JL, Kyu S, Kobie JJ, Walsh EE, Falsey AR, Randall TD, et al. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine. 2010; 28(20):3582–7. Epub 2010/03/20. https://doi.org/10.1016/j.vaccine.2010.02.088 PMID: 20298818; PubMed Central PMCID: PMC2956140.

42. Kirkpatrick BD, Bentley MD, Thern AM, Larsson CJ, Ventrone C, Sreenivasan MV, et al. Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09). Clin Diagn Lab Immunol. 2005; 12(9):1127–9. Epub 2005/09/09. https://doi.org/10.1128/CDLI.12.9.1127-1129.2005 PMID: 16148184; PubMed Central PMCID: PMC1235803.

43. Raqib R, Mondal D, Karim MA, Chowdhury F, Ahmed S, Luby S, et al. Detection of antibodies secreted from circulating Mycobacterium tuberculosis-specific plasma cells in the diagnosis of pediatric tuberculosis. Clin Vaccine Immunol. 2009; 16(4):521–7. Epub 2009/02/06. https://doi.org/10.1128/CVI.00391-08 PMID: 19193833; PubMed Central PMCID: PMC2668278.

44. Raqib R, Rahman J, Kamaluddin AK, Kamal SM, Baru FA, Ahmed S, et al. Rapid diagnosis of active tuberculosis by detecting antibodies from lymphocyte secretions. J Infect Dis. 2003; 188(3):364–70. Epub 2003/07/19. https://doi.org/10.1086/376511 PMID: 12870117.

45. Thomas T, Brighenti S, Andersson J, Sack D, Raqib R. A new potential biomarker for childhood tuberculosis. Thorax. 2011; 66(8):727–9. Epub 2011/01/14. https://doi.org/10.1136/thx.2010.147363 PMID: 21228421.